British Journal of Haematology · 2014 · 12 citations · 23 references
MedicineMolecular BiologyOncologyGene ExpressionMolecular OncologyStem Cell BiologyCancer ImmunotherapyCancer Stem Cell BiologyCancer Stem CellsMultiple MyelomaStem Cell TumorigenicityTumor-associated AntigensCancer AntigensCancer Stem Cell BiomarkersCancer Stem Cell MarkersCancer Stem-like CellsCancer/testis Antigen ExpressionColony-forming Unit AssaysMolecular Drug ResistanceMyeloma Pathogenesis
Multiple myeloma (MM) stem cells, proposed to be responsible for the tumourigenesis, drug resistance and recurrence of this disease, are enriched in the cancer stem cell-like side population (SP). Cancer testis antigens (CTA) are attractive targets for immunotherapy because they are widely expressed in cancers but only in limited types of normal tissues. We designed a high throughput assay, which allowed simultaneous relative quantifying expression of 90 CTA genes associated with MM. In the three MM cell lines tested, six CTA genes were over-expressed in two and LUZP4 and ODF1 were universally up-regulated in all three cell lines. Subsequent study of primary bone marrow (BM) from eight MM patients and four healthy donors revealed that 19 CTA genes were up-regulated in SP of MM compared with mature plasma cells. In contrast, only two CTA genes showed a moderate increase in SP cells of healthy BM. Furthermore, knockdown using small interfering RNA (siRNA) revealed that LUZP4 expression is required for colony-forming ability and drug resistance in MM cells. Our findings indicate that multiple CTA have unique expression profiles in MM SP, suggesting that CTA may serve as targets for immunotherapy that it specific for MM stem cells and which may lead to the long-term cure of MM.
23
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2007 · 7.5K citations · Full text
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
Pierre van der Bruggen, Catia Traversari, Patrick Chomez et al. · Science · 1991 · 3.5K citations
Life Sciences, Immunology, Oncology +17
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text
Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
William Matsui, Qiuju Wang, James Barber et al. · Cancer Research · 2008 · 538 citations · Full text
Medicine, Oncology, Pharmacology +15